Navigation Links
Synedgen Announces Issuance of Patent to Optimize Animal Health
Date:3/22/2013

Claremont CA (PRWEB) March 22, 2013

Synedgen Inc., a bio-pharmaceutical company developing novel therapies to prevent and treat infection and inflammation, announces that the United States Patent and Trademark Office (USPTO) has issued patent claims for the use of chitosan derivatives to treat or inhibit infections, and optimize animal health and weight gain to allow for the use of lower doses of antibacterial agents in animal feed. This issuance, U.S. Patent No. 8,399,635 Chitosan derivatives to treat animals or optimize animal health, continues the expansion of Synedgen’s patent portfolio.

The full patent covers methods of inhibiting the growth of or killing of bacteria, reducing bacterial load, preventing or delaying the onset of an infection, disease or disorder in an animal subject, and includes preparation, dosage and administration methods.

“The issuance of these claims enhances the strength of our growing IP portfolio,” stated Synedgen President Shenda Baker. “It describes the utility of our chitosan derivatives for infection control in food animals as well as the ability to synergize with traditional antibiotics used in their feed, dramatically reducing the amount of antibiotic used. These claims also complement the launch of Synoplex®, Synedgen’s veterinary wound rinse product designed to treat infected, chronic and non-infected wounds in elephants and rhinoceros.”

About Synedgen
Synedgen Inc. is an innovative biopharmaceutical company focused on developing novel therapies and products through its proprietary biomaterials technology platform. Product development is targeted to specifically address unmet needs for therapies to treat inflammation, damage or infection at dermal, pulmonary and gastrointestinal surfaces.

Synedgen’s Corporate Headquarters, Research Laboratories and Manufacturing Facility are in Claremont CA. Additional information can be found at Synedgen’s web site at http://www.synedgen.com

Read the full story at http://www.prweb.com/releases/2013/3/prweb10558965.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Synedgen’s Synoplex® Receives FDA Indexing for Use in the Treatment of Chronic Wounds in Pachyderms
2. Piramal Imaging Announces the Acceptance for Review of [18F] florbetaben by the FDA and EMA for the Visual Detection of beta-amyloid in Alzheimers Disease
3. Probiotic Action Announces Probiotics Pending Listing on EU Foods
4. Butamax Announces Immediate Appeal of Court Decisions on Claim Construction and Summary Judgment
5. Neogen Corporation Announces 3rd Quarter Results Conference Call
6. Medifirst Solutions, Inc. Announces Further Update To Shareholders
7. Elsevier Announces the Launch of a New Journal: Wound Medicine
8. TaxOps Announces Partner Appointment to Prominent International Position with Fortune 100 Company
9. Amgen Announces Top-Line Results Of Phase 3 Talimogene Laherparepvec Trial In Melanoma
10. ChanTest Announces a Complimentary Webinar on the Use of the xCELLigence System
11. NineSigma Announces Winners in $25,000 Sustainable Packaging Challenge in Conjunction With Scientists Without Borders and Partners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... 2016 , ... Supplyframe, the Industry Network for electronics hardware ... . Located in Pasadena, Calif., the Design Lab’s mission is to bring together ... built and brought to market. , The Design Lab is Supplyframe’s physical representation ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the ... the Dow Jones Industrial Average edged 0.27% lower to finish ... 0.17%. Stock-Callers.com has initiated coverage on the following equities: Infinity ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... ). Learn more about these stocks by accessing their free ...
Breaking Biology Technology:
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
Breaking Biology News(10 mins):